TEAMWORK IS SUCCESSFUL (3): IMMUNOTHERAPY WITH IMMUNE CHECKPOINT INHIBITORS (ICIs) FAVOURABLE RESPONSE AND CARDIOVASCULAR COMPLICATION. A CASE REPORT
Anno:
2023
Immunotherapy in recent years has revolutionized the oncology practice. ICIs targeting T lymphocyte antigen-4 (CTLA-4) and programmed death-1/ligand-1 (PD-1/PD-L1) transformed treatment landscape of many different cancers. The answers occur in a substantial fraction of patients and are often durable. ICI's combined block (CB) (CTLA-4 + PD-1/PD-L1) seems to improve…